These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

169 related items for PubMed ID: 2112533

  • 1. Characteristics of aztreonam as a substrate, inhibitor and inducer for beta-lactamases.
    Sakurai Y, Yoshida Y, Saitoh K, Nemoto M, Yamaguchi A, Sawai T.
    J Antibiot (Tokyo); 1990 Apr; 43(4):403-10. PubMed ID: 2112533
    [Abstract] [Full Text] [Related]

  • 2. Mechanism of beta-lactamase inhibition: differences between sulbactam and other inhibitors.
    Sawai T, Yamaguchi A.
    Diagn Microbiol Infect Dis; 1989 Apr; 12(4 Suppl):121S-129S. PubMed ID: 2591172
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Cefoxitin, N-formimidoyl thienamycin, clavulanic acid, and penicillanic acid sulfone as suicide inhibitors for different types of beta-lactamases produced by gram-negative bacteria.
    Sawai T, Tsukamoto K.
    J Antibiot (Tokyo); 1982 Nov; 35(11):1594-602. PubMed ID: 6298169
    [Abstract] [Full Text] [Related]

  • 5. Incidence of inducible beta-lactamases in gram-negative septicemia isolates from twenty-nine European laboratories. European Study Group on Antibiotic Resistance.
    Eur J Clin Microbiol; 1987 Aug; 6(4):460-6. PubMed ID: 3117535
    [Abstract] [Full Text] [Related]

  • 6. Beta-lactamase stability and antibacterial activity of cefmenoxime (SCE-1365), a novel cephalosporin.
    Okonogi K, Kuno M, Kida M, Mitsuhashi S.
    Antimicrob Agents Chemother; 1981 Aug; 20(2):171-5. PubMed ID: 6269488
    [Abstract] [Full Text] [Related]

  • 7. Sulbactam: biochemical factors involved in its synergy with ampicillin.
    Labia R, Morand A, Lelievre V, Mattioni D, Kazmierczak A.
    Rev Infect Dis; 1986 Aug; 8 Suppl 5():S496-502. PubMed ID: 3025996
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Effects of beta-lactamases and omp mutation on susceptibility to beta-lactam antibiotics in Escherichia coli.
    Hiraoka M, Okamoto R, Inoue M, Mitsuhashi S.
    Antimicrob Agents Chemother; 1989 Mar; 33(3):382-6. PubMed ID: 2658786
    [Abstract] [Full Text] [Related]

  • 12. Antibacterial activity of T-5575, a novel 2-carboxypenam, and its stability to beta-lactamase.
    Matsumura N, Minami S, Mitsuhashi S.
    J Antimicrob Chemother; 1997 Jan; 39(1):31-4. PubMed ID: 9044025
    [Abstract] [Full Text] [Related]

  • 13. Extension of the substrate spectrum by an amino acid substitution at residue 219 in the Citrobacter freundii cephalosporinase.
    Tsukamoto K, Ohno R, Sawai T.
    J Bacteriol; 1990 Aug; 172(8):4348-51. PubMed ID: 2115867
    [Abstract] [Full Text] [Related]

  • 14. New Delhi metallo-β-lactamase (NDM-1): an update.
    Shakil S, Azhar EI, Tabrez S, Kamal MA, Jabir NR, Abuzenadah AM, Damanhouri GA, Alam Q.
    J Chemother; 2011 Oct; 23(5):263-5. PubMed ID: 22005056
    [Abstract] [Full Text] [Related]

  • 15. Antibacterial activity of tigemonam dicholate (SQ 30836) and interaction with beta-lactamases of gram-negative bacteria.
    Raimondi A, Cocuzza CE.
    J Chemother; 1989 May; 1 Suppl 2():13-21. PubMed ID: 2809698
    [Abstract] [Full Text] [Related]

  • 16. Amdinocillin: interaction with other beta-lactam antibiotics for gram-negative bacteria.
    Eng RH, Liu R, Smith SM, Johnson ES, Cherubin CE.
    Chemotherapy; 1988 May; 34(1):18-26. PubMed ID: 3258230
    [Abstract] [Full Text] [Related]

  • 17. Novel carbapenem derivative SF2103A: studies on the mode of beta-lactamase inactivation.
    Yamaguchi A, Hirata T, Sawai T.
    Antimicrob Agents Chemother; 1984 Mar; 25(3):348-53. PubMed ID: 6372682
    [Abstract] [Full Text] [Related]

  • 18. Plasmid-mediated beta-lactamase (TEM-7) involved in resistance to ceftazidime and aztreonam.
    Gutmann L, Kitzis MD, Billot-Klein D, Goldstein F, Tran Van Nhieu G, Lu T, Carlet J, Collatz E, Williamson R.
    Rev Infect Dis; 1988 Mar; 10(4):860-6. PubMed ID: 3055178
    [Abstract] [Full Text] [Related]

  • 19. Inhibitory activity of avibactam against selected β-lactamases expressed in an isogenic Escherichia coli strain.
    Giani T, Cannatelli A, Di Pilato V, Testa R, Nichols WW, Rossolini GM.
    Diagn Microbiol Infect Dis; 2016 Sep; 86(1):83-5. PubMed ID: 27394638
    [Abstract] [Full Text] [Related]

  • 20. The postantibiotic effect and post-β-lactamase-inhibitor effect of ceftazidime, ceftaroline and aztreonam in combination with avibactam against target Gram-negative bacteria.
    Pillar CM, Stoneburner A, Shinabarger DL, Krause KM, Nichols WW.
    Lett Appl Microbiol; 2016 Aug; 63(2):96-102. PubMed ID: 27221329
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.